Related Experiment Videos
Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study
Fiona H Blackhall1, Dennis A Wigle, Igor Jurisica
1Division of Cellular and Molecular Biology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9.
Lung Cancer (Amsterdam, Netherlands)
|October 12, 2004
Summary
Microarray analysis identified potential lung cancer recurrence markers. Real-time RT-PCR partially validated these markers, but larger studies are needed to confirm their prognostic value in non-small cell lung carcinoma (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Previous cDNA microarray analysis identified candidate prognostic markers for non-small cell lung carcinoma (NSCLC) recurrence.
- Gene expression profiling is crucial for understanding cancer progression and identifying therapeutic targets.
Purpose of the Study:
- To validate candidate prognostic marker genes identified by microarray analysis using real-time reverse transcription polymerase chain reaction (RT-PCR).
- To assess the prognostic significance of selected genes in a cohort of NSCLC patients.
Main Methods:
- Real-time RT-PCR was performed on 11 candidate genes from primary NSCLC tissues.
- Cluster analysis was used to evaluate gene expression patterns and survival data.
- Univariate and multivariate analyses were conducted to identify significant prognostic factors.
Main Results:
- Cluster analysis of RT-PCR data separated patients into two groups with significantly different disease-free survivals (P < 0.017).
- Prognostic significance was not confirmed in a validation series of 92 NSCLC cases.
- Hypoxia inducible factor 1alpha, Rho-GDP dissociation inhibitor alpha (RhoGDI), and Citron/rho-interacting serine-threonine kinase 21 (Citron K21) showed univariate significance but not multivariate significance.
Conclusions:
- Real-time RT-PCR can partially validate prognostic marker genes identified by microarray analysis.
- Secondary validation in larger, independent NSCLC patient series is essential to confirm true prognostic marker genes.
- Further research is needed to identify reliable prognostic markers for NSCLC recurrence.